Cargando…

A novel prognostic model for Japanese patients with newly diagnosed bone‐metastatic hormone‐naïve prostate cancer

OBJECTIVES: To evaluate the prognosis of newly diagnosed patients with metastatic hormone‐naïve prostate cancer (mHNPC) and develop a novel prognostic model based on ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) risk classificatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyoshi, Yasuhide, Yasui, Masato, Yoneyama, Shuko, Kawahara, Takashi, Nakagami, Yoshihiro, Ohno, Yoshimasa, Iizuka, Junpei, Tanabe, Kazunari, Hashimoto, Yasunobu, Tsumura, Hideyasu, Tabata, Ken‐ichi, Iwamura, Masatsugu, Yano, Akihiro, Kawakami, Satoru, Uemura, Hiroji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988841/ https://www.ncbi.nlm.nih.gov/pubmed/35474890 http://dx.doi.org/10.1002/bco2.46

Ejemplares similares

Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study
por: Kawahara, Takashi, et al.
Publicado: (2020)

Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
por: Kawahara, Takashi, et al.
Publicado: (2023)

A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment
por: Kawahara, Takashi, et al.
Publicado: (2020)

Prognostic value of automated bone scan index for predicting overall survival among bone metastatic castration resistant prostate cancer patients treated with radium‐223
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

A lower psoas muscle index predicts a poorer prognosis in metastatic hormone‐naïve prostate cancer
por: Iwamoto, Genta, et al.
Publicado: (2020)

Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases
por: Miyoshi, Yasuhide, et al.
Publicado: (2016)

Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Uemura, Koichi, et al.
Publicado: (2018)

A cold spot compensation technique using a combination of trans-rectal ultrasonography and intraoperative computed tomography for interstitial permanent prostate brachytherapy: a single-arm prospective trial
por: Ishiyama, Hiromichi, et al.
Publicado: (2018)

A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer
por: Kainuma, Takuro, et al.
Publicado: (2019)

A high serum dehydroepiandrosterone concentration is a predictor of candidates for active surveillance in men with serum prostate-specific antigen < 10 ng/mL
por: Miyoshi, Yasuhide, et al.
Publicado: (2022)

Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
por: Koguchi, Dai, et al.
Publicado: (2021)

Comparison of prostate contours between conventional stepping transverse imaging and Twister-based sagittal imaging in permanent interstitial prostate brachytherapy
por: Kawakami, Shogo, et al.
Publicado: (2017)

(125)Iodine monotherapy for Japanese men with low- and intermediate-risk prostate cancer: outcomes after 5 years of follow-up
por: Sekiguchi, Akane, et al.
Publicado: (2014)

Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis
por: Yamada, Yoko, et al.
Publicado: (2016)

The Achievement of Long-Term CRPC Control in a Patient with Enzalutamide-Induced Nausea and Fatigue after Overcoming the Adverse Events with a Temporary Drug Holiday
por: Kawahara, Takashi, et al.
Publicado: (2019)

Clinical outcome of surgical management for symptomatic metastatic spinal cord compression from prostate cancer
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

Changing the Timing of Enzalutamide Intake from Morning to before Sleep at Night Overcame Enzalutamide-Induced Dysgeusia
por: Kawahara, Takashi, et al.
Publicado: (2019)

Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer
por: Uemura, Koichi, et al.
Publicado: (2016)

Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide
por: Kumano, Yohei, et al.
Publicado: (2019)

Dosimetry of permanent interstitial prostate brachytherapy for an interoperative procedure, using O-arm based CT and TRUS
por: Ishiyama, Hiromichi, et al.
Publicado: (2016)

Dosimetric Predictors of Toxicity after Prostate Stereotactic Body Radiotherapy: A Single-Institutional Experience of 145 Patients
por: Fujii, Kyohei, et al.
Publicado: (2023)

Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
por: Kawahara, Takashi, et al.
Publicado: (2019)

Comparison of three different techniques of low-dose-rate seed implantation for prostate cancer
por: Ishiyama, Hiromichi, et al.
Publicado: (2015)

Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer
por: Yasui, Masato, et al.
Publicado: (2019)

Inserting a Metallic Ureteral Stent Using an Antegrade Approach Freed a Patient from Nephrostomy Created due to Hydronephrosis Caused by Bladder Cancer
por: Kawahara, Takashi, et al.
Publicado: (2019)

Changing the enzalutamide form from a capsule to a tablet improves the adherence of medicine intake: A case of a significant decrease in the prostate‐specific antigen level and improvement in radiographic findings
por: Kawahara, Takashi, et al.
Publicado: (2019)

A retrospective study on the possible systematic inflammatory response markers to predict the prognosis of patients with bladder cancer undergoing radial cystectomy
por: Ninomiya, Sahoko, et al.
Publicado: (2020)

Longer Control of Nivolumab in Metastatic Renal Cell Carcinoma Patients with End-Stage Kidney Disease on Dialysis
por: Morinaga, Ryota, et al.
Publicado: (2019)

A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer
por: Miyoshi, Yasuhide, et al.
Publicado: (2021)

Prognosis and safety of radium‐223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration‐resistant prostate cancer: Real‐world data of Japanese patients
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

A Case of Switching from GnRH Agonist to Antagonist for Castration Resistant Prostate Cancer Control
por: Sugimura, Rumiko, et al.
Publicado: (2019)

The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer
por: Iwamoto, Genta, et al.
Publicado: (2021)

Sperm cryopreservation before definitive therapy for early‐stage prostate cancer: A single institution experience
por: Miyoshi, Yasuhide, et al.
Publicado: (2022)

Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2017)

Successful Resection of Cisplatin-Resistant Renal Pelvic Cancer after the Administration of Pembrolizumab as Second-Line Therapy
por: Kawahara, Takashi, et al.
Publicado: (2019)

Clear cell adenocarcinoma of the prostatic urethra: A case report
por: Sugimura, Rumiko, et al.
Publicado: (2018)

Preference for enzalutamide capsules versus tablet pills in patients with prostate cancer
por: Ninomiya, Sahoko, et al.
Publicado: (2019)

Radiotherapy for Oligometastases and Oligo-Recurrence of Bone in Prostate Cancer
por: Tabata, Ken-ichi, et al.
Publicado: (2012)

Cytopathic effects and local immune responses in repeated neoadjuvant HSV-tk + ganciclovir gene therapy for prostate cancer
por: Yanagisawa, Nobuyuki, et al.
Publicado: (2021)

Phase I trial of TAK‐385 in hormone treatment‐naïve Japanese patients with nonmetastatic prostate cancer
por: Suzuki, Hiroyoshi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3a01d1n0gpiqclbkbs5l2447kg